Dimethyl sulfoxide

Specific investigations: other studies

Link to relevant study record(s)

Reference

Reference 1

Endpoint:

biochemical or cellular interactions

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: data from iCSS CompTox Dashboard. Data Quality 100%. Data manually curated with highest confidence

Principles of method if other than guideline:

Using a high-throughput robotic screening system, DMDO was assessed for its potential to disrupt biological pathways (DNA binding, growth factor, nuclear receptor (non-steroidal and steroidal), cell cycle, cytochrome P450, hydrolase and cell morphology) that may result in toxicity.

Type of method:

in vitro

Specific details on test material used for the study:

DSSTOX GSID: 21735

Remarks:

0.001 to 200µM

Details on study design:

See enclosed excel file

Details on results:

316 assays were performed, DMSO induced a positive response in 2 assays (ATG_Ahr_CIS_up and NVS_ADME_hCYP19A1). In the NVS_ADME_hCYP19A1 assay, the biochemical assay was < 50% efficacy and both assays were flagged as borderline activity. Therefore, there is no evidence that DMSO could interfere with the expression of the screened genes.

316 assays were performed, all results are displayed in the enclosed excel file.

Dimethyl sulphoxide induce a positive respons in 2 assay (see attached figure and table).

 

Intended Target Family	Assay Component Endpoint Name	AC50 (µM)	LogAC50	Result
cell cycle	ACEA_T47D_80hr_Negative	>100		Inactive
nuclear receptor	ACEA_T47D_80hr_Positive	>100		Inactive
dna binding	ATG_AP_1_CIS_dn	>100		Inactive
dna binding	ATG_AP_1_CIS_up	>100		Inactive
dna binding	ATG_AP_2_CIS_dn	>100		Inactive
dna binding	ATG_AP_2_CIS_up	>100		Inactive
nuclear receptor	ATG_AR_TRANS_dn	>100		Inactive
nuclear receptor	ATG_AR_TRANS_up	>100		Inactive
dna binding	ATG_Ahr_CIS_dn	>100		Inactive
dna binding	ATG_Ahr_CIS_up	1.76642438	1.23330695	Active
dna binding	ATG_BRE_CIS_dn	>100		Inactive
dna binding	ATG_BRE_CIS_up	>100		Inactive
nuclear receptor	ATG_CAR_TRANS_dn	>100		Inactive
nuclear receptor	ATG_CAR_TRANS_up	>100		Inactive
background measurement	ATG_CMV_CIS_dn	>100		Inactive
background measurement	ATG_CMV_CIS_up	>100		Inactive
dna binding	ATG_CRE_CIS_dn	>100		Inactive
dna binding	ATG_CRE_CIS_up	>100		Inactive
dna binding	ATG_C_EBP_CIS_dn	>100		Inactive
dna binding	ATG_C_EBP_CIS_up	>100		Inactive
nuclear receptor	ATG_DR5_CIS_dn	>100		Inactive
dna binding	ATG_E2F_CIS_dn	>100		Inactive
dna binding	ATG_E2F_CIS_up	>100		Inactive
dna binding	ATG_EGR_CIS_dn	>100		Inactive
dna binding	ATG_EGR_CIS_up	>100		Inactive
nuclear receptor	ATG_ERE_CIS_dn	1.86335	0.70526483	Inactive
nuclear receptor	ATG_ERE_CIS_up	>100		Inactive
nuclear receptor	ATG_ERRa_TRANS_dn	>100		Inactive
nuclear receptor	ATG_ERRa_TRANS_up	>100		Inactive
nuclear receptor	ATG_ERRg_TRANS_dn	>100		Inactive
nuclear receptor	ATG_ERRg_TRANS_up	>100		Inactive
nuclear receptor	ATG_ERa_TRANS_dn	>100		Inactive
nuclear receptor	ATG_ERa_TRANS_up	>100		Inactive
dna binding	ATG_E_Box_CIS_dn	>100		Inactive
dna binding	ATG_E_Box_CIS_up	>100		Inactive
dna binding	ATG_Ets_CIS_dn	>100		Inactive
dna binding	ATG_Ets_CIS_up	>100		Inactive
nuclear receptor	ATG_FXR_TRANS_dn	>100		Inactive
nuclear receptor	ATG_FXR_TRANS_up	>100		Inactive
dna binding	ATG_FoxA2_CIS_dn	>100		Inactive
dna binding	ATG_FoxA2_CIS_up	>100		Inactive
dna binding	ATG_FoxO_CIS_dn	>100		Inactive
dna binding	ATG_FoxO_CIS_up	>100		Inactive
background measurement	ATG_GAL4_TRANS_dn	>100		Inactive
background measurement	ATG_GAL4_TRANS_up	>100		Inactive
dna binding	ATG_GATA_CIS_dn	>100		Inactive
dna binding	ATG_GATA_CIS_up	1.36529001	0.47689725	Inactive
dna binding	ATG_GLI_CIS_dn	>100		Inactive
dna binding	ATG_GLI_CIS_up	>100		Inactive
nuclear receptor	ATG_GR_TRANS_dn	>100		Inactive
nuclear receptor	ATG_GR_TRANS_up	>100		Inactive
dna binding	ATG_HIF1a_CIS_dn	>100		Inactive
dna binding	ATG_HIF1a_CIS_up	-2.60376115	0.71408501	Inactive
nuclear receptor	ATG_HNF4a_TRANS_dn	>100		Inactive
nuclear receptor	ATG_HNF4a_TRANS_up	>100		Inactive
dna binding	ATG_HNF6_CIS_dn	>100		Inactive
dna binding	ATG_HNF6_CIS_up	>100		Inactive
dna binding	ATG_HSE_CIS_dn	>100		Inactive
dna binding	ATG_HSE_CIS_up	>100		Inactive
nuclear receptor	ATG_IR1_CIS_dn	>100		Inactive
nuclear receptor	ATG_IR1_CIS_up	>100		Inactive
dna binding	ATG_ISRE_CIS_dn	>100		Inactive
dna binding	ATG_ISRE_CIS_up	>100		Inactive
nuclear receptor	ATG_LXRa_TRANS_up	>100		Inactive
nuclear receptor	ATG_LXRb_TRANS_dn	>100		Inactive
nuclear receptor	ATG_LXRb_TRANS_up	>100		Inactive
dna binding	ATG_MRE_CIS_dn	>100		Inactive
dna binding	ATG_MRE_CIS_up	>100		Inactive
background measurement	ATG_M_06_CIS_dn	>100		Inactive
background measurement	ATG_M_06_CIS_up	>100		Inactive
background measurement	ATG_M_06_TRANS_dn	>100		Inactive
background measurement	ATG_M_06_TRANS_up	>100		Inactive
background measurement	ATG_M_19_CIS_dn	>100		Inactive
background measurement	ATG_M_19_CIS_up	>100		Inactive
background measurement	ATG_M_19_TRANS_dn	>100		Inactive
background measurement	ATG_M_19_TRANS_up	>100		Inactive
background measurement	ATG_M_32_CIS_dn	>100		Inactive
background measurement	ATG_M_32_CIS_up	>100		Inactive
background measurement	ATG_M_32_TRANS_dn	>100		Inactive
background measurement	ATG_M_32_TRANS_up	>100		Inactive
background measurement	ATG_M_61_CIS_dn	>100		Inactive
background measurement	ATG_M_61_CIS_up	>100		Inactive
background measurement	ATG_M_61_TRANS_dn	>100		Inactive
background measurement	ATG_M_61_TRANS_up	>100		Inactive
dna binding	ATG_Myb_CIS_dn	>100		Inactive
dna binding	ATG_Myb_CIS_up	>100		Inactive
dna binding	ATG_Myc_CIS_dn	>100		Inactive
dna binding	ATG_Myc_CIS_up	>100		Inactive
dna binding	ATG_NFI_CIS_dn	>100		Inactive
dna binding	ATG_NFI_CIS_up	>100		Inactive
dna binding	ATG_NF_kB_CIS_dn	>100		Inactive
dna binding	ATG_NF_kB_CIS_up	>100		Inactive
dna binding	ATG_NRF1_CIS_dn	>100		Inactive
dna binding	ATG_NRF1_CIS_up	>100		Inactive
dna binding	ATG_NRF2_ARE_CIS_dn	>100		Inactive
dna binding	ATG_NRF2_ARE_CIS_up	>100		Inactive
nuclear receptor	ATG_NURR1_TRANS_dn	>100		Inactive
nuclear receptor	ATG_NURR1_TRANS_up	>100		Inactive
dna binding	ATG_Oct_MLP_CIS_dn	>100		Inactive
dna binding	ATG_Oct_MLP_CIS_up	>100		Inactive
nuclear receptor	ATG_PBREM_CIS_dn	>100		Inactive
nuclear receptor	ATG_PBREM_CIS_up	>100		Inactive
nuclear receptor	ATG_PPARa_TRANS_dn	>100		Inactive
nuclear receptor	ATG_PPARa_TRANS_up	>100		Inactive
nuclear receptor	ATG_PPARd_TRANS_dn	>100		Inactive
nuclear receptor	ATG_PPARd_TRANS_up	>100		Inactive
nuclear receptor	ATG_PPARg_TRANS_dn	>100		Inactive
nuclear receptor	ATG_PPARg_TRANS_up	>100		Inactive
nuclear receptor	ATG_PPRE_CIS_dn	>100		Inactive
nuclear receptor	ATG_PPRE_CIS_up	>100		Inactive
nuclear receptor	ATG_PXRE_CIS_dn	>100		Inactive
nuclear receptor	ATG_PXRE_CIS_up	>100		Inactive
nuclear receptor	ATG_PXR_TRANS_dn	>100		Inactive
nuclear receptor	ATG_PXR_TRANS_up	>100		Inactive
dna binding	ATG_Pax6_CIS_dn	>100		Inactive
dna binding	ATG_Pax6_CIS_up	>100		Inactive
nuclear receptor	ATG_RARa_TRANS_dn	>100		Inactive
nuclear receptor	ATG_RARa_TRANS_up	>100		Inactive
nuclear receptor	ATG_RARb_TRANS_dn	>100		Inactive
nuclear receptor	ATG_RARb_TRANS_up	>100		Inactive
nuclear receptor	ATG_RARg_TRANS_dn	>100		Inactive
nuclear receptor	ATG_RARg_TRANS_up	>100		Inactive
nuclear receptor	ATG_RORE_CIS_dn	>100		Inactive
nuclear receptor	ATG_RORE_CIS_up	>100		Inactive
nuclear receptor	ATG_RORb_TRANS_dn	>100		Inactive
nuclear receptor	ATG_RORb_TRANS_up	>100		Inactive
nuclear receptor	ATG_RORg_TRANS_dn	>100		Inactive
nuclear receptor	ATG_RORg_TRANS_up	>100		Inactive
nuclear receptor	ATG_RXRa_TRANS_dn	>100		Inactive
nuclear receptor	ATG_RXRa_TRANS_up	>100		Inactive
nuclear receptor	ATG_RXRb_TRANS_dn	>100		Inactive
nuclear receptor	ATG_RXRb_TRANS_up	>100		Inactive
dna binding	ATG_SREBP_CIS_dn	>100		Inactive
dna binding	ATG_SREBP_CIS_up	>100		Inactive
dna binding	ATG_STAT3_CIS_dn	>100		Inactive
dna binding	ATG_STAT3_CIS_up	>100		Inactive
dna binding	ATG_Sox_CIS_dn	>100		Inactive
dna binding	ATG_Sox_CIS_up	>100		Inactive
dna binding	ATG_Sp1_CIS_dn	>100		Inactive
dna binding	ATG_Sp1_CIS_up	>100		Inactive
background measurement	ATG_TAL_CIS_dn	>100		Inactive
background measurement	ATG_TAL_CIS_up	>100		Inactive
background measurement	ATG_TA_CIS_dn	>100		Inactive
background measurement	ATG_TA_CIS_up	>100		Inactive
dna binding	ATG_TCF_b_cat_CIS_dn	>100		Inactive
dna binding	ATG_TCF_b_cat_CIS_up	>100		Inactive
growth factor	ATG_TGFb_CIS_dn	>100		Inactive
growth factor	ATG_TGFb_CIS_up	>100		Inactive
nuclear receptor	ATG_THRa1_TRANS_dn	>100		Inactive
nuclear receptor	ATG_THRa1_TRANS_up	>100		Inactive
nuclear receptor	ATG_VDRE_CIS_dn	>100		Inactive
nuclear receptor	ATG_VDRE_CIS_up	>100		Inactive
nuclear receptor	ATG_VDR_TRANS_dn	>100		Inactive
nuclear receptor	ATG_VDR_TRANS_up	>100		Inactive
cell cycle	ATG_XTT_Cytotoxicity_up	>100		Inactive
dna binding	ATG_Xbp1_CIS_dn	>100		Inactive
dna binding	ATG_Xbp1_CIS_up	>100		Inactive
dna binding	ATG_p53_CIS_dn	>100		Inactive
dna binding	ATG_p53_CIS_up	>100		Inactive
cyp	NVS_ADME_hCYP19A1	0.93735446	1.22870888	Active
cyp	NVS_ADME_hCYP19A1_Activator	>100		Inactive
nuclear receptor	NVS_NR_bER	>100		Inactive
nuclear receptor	NVS_NR_hER	>100		Inactive
nuclear receptor	NVS_NR_mERa	-1.08010089	0.85999974	Inactive
nuclear receptor	OT_AR_ARELUC_AG_1440	>100		Inactive
nuclear receptor	OT_AR_ARSRC1_0480	>100		Inactive
nuclear receptor	OT_AR_ARSRC1_0960	>100		Inactive
nuclear receptor	OT_ER_ERaERa_0480	>100		Inactive
nuclear receptor	OT_ER_ERaERa_1440	>100		Inactive
nuclear receptor	OT_ER_ERaERb_0480	>100		Inactive
nuclear receptor	OT_ER_ERaERb_1440	>100		Inactive
nuclear receptor	OT_ER_ERbERb_0480	>100		Inactive
nuclear receptor	OT_ER_ERbERb_1440	>100		Inactive
nuclear receptor	OT_ERa_EREGFP_0120	>100		Inactive
nuclear receptor	OT_ERa_EREGFP_0480	>100		Inactive
nuclear receptor	OT_FXR_FXRSRC1_0480	>100		Inactive
nuclear receptor	OT_FXR_FXRSRC1_1440	>100		Inactive
nuclear receptor	OT_NURR1_NURR1RXRa_0480	>100		Inactive
nuclear receptor	OT_NURR1_NURR1RXRa_1440	>100		Inactive
nuclear receptor	OT_PPARg_PPARgSRC1_0480	>100		Inactive
nuclear receptor	OT_PPARg_PPARgSRC1_1440	>100		Inactive
background measurement	TOX21_ARE_BLA_Agonist_ch1	>100		Inactive
background measurement	TOX21_ARE_BLA_Agonist_ch2	1.78565278	1.11859869	Inactive
dna binding	TOX21_ARE_BLA_agonist_ratio	1.83795837	1.44565386	Inactive
cell cycle	TOX21_ARE_BLA_agonist_viability	>100		Inactive
background measurement	TOX21_AR_BLA_Agonist_ch1	>100		Inactive
background measurement	TOX21_AR_BLA_Agonist_ch2	>100		Inactive
nuclear receptor	TOX21_AR_BLA_Agonist_ratio	>100		Inactive
background measurement	TOX21_AR_BLA_Antagonist_ch1	>100		Inactive
background measurement	TOX21_AR_BLA_Antagonist_ch2	-3.02166522	0.1559117	Inactive
nuclear receptor	TOX21_AR_BLA_Antagonist_ratio	>100		Inactive
cell cycle	TOX21_AR_BLA_Antagonist_viability	>100		Inactive
nuclear receptor	TOX21_AR_LUC_MDAKB2_Agonist	>100		Inactive
nuclear receptor	TOX21_AR_LUC_MDAKB2_Antagonist	>100		Inactive
dna binding	TOX21_AhR_LUC_Agonist	>100		Inactive
cyp	TOX21_Aromatase_Inhibition	1.27111531	0.40139802	Inactive
background measurement	TOX21_AutoFluor_HEK293_Cell_blue	0.61089687	0.02833535	Inactive
background measurement	TOX21_AutoFluor_HEK293_Cell_green	>100		Inactive
background measurement	TOX21_AutoFluor_HEK293_Cell_red	0.79073689	0.05699185	Inactive
background measurement	TOX21_AutoFluor_HEK293_Media_blue	>100		Inactive
background measurement	TOX21_AutoFluor_HEK293_Media_green	0.45262469	0.007909	Inactive
background measurement	TOX21_AutoFluor_HEK293_Media_red	>100		Inactive
background measurement	TOX21_AutoFluor_HEPG2_Cell_blue	>100		Inactive
background measurement	TOX21_AutoFluor_HEPG2_Cell_green	>100		Inactive
background measurement	TOX21_AutoFluor_HEPG2_Cell_red	>100		Inactive
background measurement	TOX21_AutoFluor_HEPG2_Media_blue	>100		Inactive
background measurement	TOX21_AutoFluor_HEPG2_Media_green	>100		Inactive
background measurement	TOX21_AutoFluor_HEPG2_Media_red	>100		Inactive
hydrolase	TOX21_ELG1_LUC_Agonist	>100		Inactive
background measurement	TOX21_ERa_BLA_Agonist_ch1	>100		Inactive
background measurement	TOX21_ERa_BLA_Agonist_ch2	>100		Inactive
nuclear receptor	TOX21_ERa_BLA_Agonist_ratio	>100		Inactive
background measurement	TOX21_ERa_BLA_Antagonist_ch1	>100		Inactive
background measurement	TOX21_ERa_BLA_Antagonist_ch2	>100		Inactive
nuclear receptor	TOX21_ERa_BLA_Antagonist_ratio	1.60457702	0.34364255	Inactive
cell cycle	TOX21_ERa_BLA_Antagonist_viability	>100		Inactive
nuclear receptor	TOX21_ERa_LUC_BG1_Agonist	>100		Inactive
nuclear receptor	TOX21_ERa_LUC_BG1_Antagonist	>100		Inactive
background measurement	TOX21_ESRE_BLA_ch1	>100		Inactive
background measurement	TOX21_ESRE_BLA_ch2	>100		Inactive
dna binding	TOX21_ESRE_BLA_ratio	>100		Inactive
cell cycle	TOX21_ESRE_BLA_viability	>100		Inactive
background measurement	TOX21_FXR_BLA_Antagonist_ch1	>100		Inactive
background measurement	TOX21_FXR_BLA_Antagonist_ch2	>100		Inactive
background measurement	TOX21_FXR_BLA_agonist_ch1	>100		Inactive
background measurement	TOX21_FXR_BLA_agonist_ch2	>100		Inactive
nuclear receptor	TOX21_FXR_BLA_agonist_ratio	>100		Inactive
cell cycle	TOX21_FXR_BLA_agonist_viability	>100		Inactive
nuclear receptor	TOX21_FXR_BLA_antagonist_ratio	>100		Inactive
cell cycle	TOX21_FXR_BLA_antagonist_viability	>100		Inactive
background measurement	TOX21_GR_BLA_Agonist_ch1	>100		Inactive
background measurement	TOX21_GR_BLA_Agonist_ch2	>100		Inactive
nuclear receptor	TOX21_GR_BLA_Agonist_ratio	>100		Inactive
background measurement	TOX21_GR_BLA_Antagonist_ch1	>100		Inactive
background measurement	TOX21_GR_BLA_Antagonist_ch2	>100		Inactive
nuclear receptor	TOX21_GR_BLA_Antagonist_ratio	>100		Inactive
cell cycle	TOX21_GR_BLA_Antagonist_viability	>100		Inactive
background measurement	TOX21_HSE_BLA_agonist_ch1	>100		Inactive
background measurement	TOX21_HSE_BLA_agonist_ch2	>100		Inactive
dna binding	TOX21_HSE_BLA_agonist_ratio	>100		Inactive
cell cycle	TOX21_HSE_BLA_agonist_viability	>100		Inactive
cell morphology	TOX21_MMP_ratio_down	>100		Inactive
cell morphology	TOX21_MMP_ratio_up	0.74481946	0.34222594	Inactive
cell cycle	TOX21_MMP_viability	>100		Inactive
background measurement	TOX21_NFkB_BLA_agonist_ch1	>100		Inactive
background measurement	TOX21_NFkB_BLA_agonist_ch2	>100		Inactive
dna binding	TOX21_NFkB_BLA_agonist_ratio	>100		Inactive
cell cycle	TOX21_NFkB_BLA_agonist_viability	>100		Inactive
cell cycle	TOX21_PPARd_BLA_Agonist_viability	>100		Inactive
background measurement	TOX21_PPARd_BLA_Antagonist_ch1	>100		Inactive
background measurement	TOX21_PPARd_BLA_Antagonist_ch2	>100		Inactive
background measurement	TOX21_PPARd_BLA_agonist_ch1	>100		Inactive
background measurement	TOX21_PPARd_BLA_agonist_ch2	>100		Inactive
nuclear receptor	TOX21_PPARd_BLA_agonist_ratio	>100		Inactive
nuclear receptor	TOX21_PPARd_BLA_antagonist_ratio	1.58391519	0.75071519	Inactive
cell cycle	TOX21_PPARd_BLA_antagonist_viability	>100		Inactive
background measurement	TOX21_PPARg_BLA_Agonist_ch1	>100		Inactive
background measurement	TOX21_PPARg_BLA_Agonist_ch2	>100		Inactive
nuclear receptor	TOX21_PPARg_BLA_Agonist_ratio	-0.16499306	0.14944656	Inactive
background measurement	TOX21_PPARg_BLA_Antagonist_ch1	>100		Inactive
background measurement	TOX21_PPARg_BLA_Antagonist_ch2	>100		Inactive
nuclear receptor	TOX21_PPARg_BLA_antagonist_ratio	>100		Inactive
cell cycle	TOX21_PPARg_BLA_antagonist_viability	>100		Inactive
nuclear receptor	TOX21_TR_LUC_GH3_Agonist	>100		Inactive
nuclear receptor	TOX21_TR_LUC_GH3_Antagonist	>100		Inactive
cell cycle	TOX21_VDR_BLA_Agonist_viability	>100		Inactive
background measurement	TOX21_VDR_BLA_Antagonist_ch1	>100		Inactive
background measurement	TOX21_VDR_BLA_Antagonist_ch2	>100		Inactive
background measurement	TOX21_VDR_BLA_agonist_ch1	>100		Inactive
background measurement	TOX21_VDR_BLA_agonist_ch2	>100		Inactive
cyp	TOX21_VDR_BLA_agonist_ratio	>100		Inactive
cyp	TOX21_VDR_BLA_antagonist_ratio	>100		Inactive
cell cycle	TOX21_VDR_BLA_antagonist_viability	>100		Inactive
background measurement	TOX21_p53_BLA_p1_ch1	>100		Inactive
background measurement	TOX21_p53_BLA_p1_ch2	>100		Inactive
dna binding	TOX21_p53_BLA_p1_ratio	>100		Inactive
cell cycle	TOX21_p53_BLA_p1_viability	>100		Inactive
background measurement	TOX21_p53_BLA_p2_ch1	>100		Inactive
background measurement	TOX21_p53_BLA_p2_ch2	>100		Inactive
dna binding	TOX21_p53_BLA_p2_ratio	>100		Inactive
cell cycle	TOX21_p53_BLA_p2_viability	>100		Inactive
background measurement	TOX21_p53_BLA_p3_ch1	>100		Inactive
background measurement	TOX21_p53_BLA_p3_ch2	>100		Inactive
dna binding	TOX21_p53_BLA_p3_ratio	>100		Inactive
cell cycle	TOX21_p53_BLA_p3_viability	>100		Inactive
background measurement	TOX21_p53_BLA_p4_ch1	>100		Inactive
background measurement	TOX21_p53_BLA_p4_ch2	>100		Inactive
dna binding	TOX21_p53_BLA_p4_ratio	>100		Inactive
cell cycle	TOX21_p53_BLA_p4_viability	>100		Inactive
background measurement	TOX21_p53_BLA_p5_ch1	>100		Inactive
background measurement	TOX21_p53_BLA_p5_ch2	>100		Inactive
dna binding	TOX21_p53_BLA_p5_ratio	>100		Inactive
cell cycle	TOX21_p53_BLA_p5_viability	>100		Inactive
null	undefined	>100		Inactive
nuclear receptor	ATG_DR4_LXR_CIS_dn	>100		Inactive
nuclear receptor	ATG_DR4_LXR_CIS_up	>100		Inactive
nuclear receptor	ATG_DR5_CIS_up	>100		Inactive
nuclear receptor	ATG_GRE_CIS_dn	>100		Inactive
nuclear receptor	ATG_GRE_CIS_up	>100		Inactive
nuclear receptor	ATG_LXRa_TRANS_dn	>100		Inactive

Executive summary:

Using a high-throughput robotic screening system, DMSO was assessed for its potential to disrupt biological pathways (DNA binding, growth factor, nuclear receptor (non-steroidal and steroidal), cell cycle, cytochrome P450, hydrolase and cell morphology) that may result in toxicity. 316 assays were performed, DMSO induced a positive response in 2 assays (ATG_Ahr_CIS_up and NVS_ADME_hCYP19A1). In the NVS_ADME_hCYP19A1 assay, the biochemical assay was < 50% efficacy and both assays were flagged as borderline activity. Therefore, there is no evidence that DMSO could interfere with the expression of the screened genes.

Reference 2

Endpoint:

biochemical or cellular interactions

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

2 (reliable with restrictions)

Principles of method if other than guideline:

The PubChem BioAssay database was searched for chemogenomic, medicinal chemistry and functional genomics biological activities

Type of method:

in vivo

Specific details on test material used for the study:

PubChem CID: 679
PubChem SID: 67640, 48414927, 26757375, 103172948, 144211274, 316919445

Details on results:

429 bioassays with 440 bioactivity outcomes were retrieved from the PubChem BioAssay data base. DMSO was reported as inactive in 195 assays, inconclusive in 25 assays and active in 5 bioassays. Activity was unspecified for 215 assays. None of the reported positive assays was demonstrative of a toxicological activity.

The list of all the assays performed is displayed in the enclosed excel file.

Detailed data on the assays reported as positive:

Activity Value [µM]	Substance SID	BioAssay AID	BioAssay Name	Target
	67640	196	NCI In Vivo Anticancer Drug Screen. Data for tumor model B16 Melanoma (intracerebral) in B6D2F1 (BDF1) mice
	67640	212	NCI In Vivo Anticancer Drug Screen. Data for tumor model Colon Carcinoma 38 (subcutaneous) in B6D2F1 (BDF1) mice
	48414927	1188	DSSTox (EPAFHM) EPA Fathead Minnow Acute Toxicity
61.1306	144211274	743219	qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary	NFE2L2
	103172948	1159620	Summary of drug indications.

Data for SID 67640 in AID 196

schedule	Q01DX005 (ip)
endpoint	median survival time
vehicle	saline
dose	8000.0 mg/kg/injection
tcprcnt	487
toxicity	Antitumor endpoint evaluated on day 60; 09/10 animals surviving on day 5

 

Data for SID 67640 in AID 212

schedule	Q07DX003 (ip)
endpoint	median tumor weight (est.)
vehicle	saline
dose	12.0 grams/kg/injection
tcprcnt	171
toxicity	Antitumor endpoint evaluated on day 20; 10/10 animals surviving on tox evaluation day (usually day 5)

 

Data for SID 48414927 in AID 1188

LC50_mg [mg/l]	34000
LC50_mmol [mmol/l]	435
MOA	Baseline narcosis
MOA_Confidence	Moderate

 

Data for SID 144211274 in AID 743219

Activity Summary	active agonist
Ratio Activity	active agonist
Ratio Potency (uM) [uM]*	61.1306
Ratio Efficacy (%) [%]	29.2951
530 nm Activity	inactive
530 nm Potency (uM) [uM]
530 nm Efficacy (%) [%]	0
460 nm Activity	inconclusive agonist
460 nm Potency (uM) [uM]	61.1306
460 nm Efficacy (%) [%]	62.7706
Viability Activity	inactive
Viability Potency (uM) [uM]
Viability Efficacy (%) [%]	0
Blue (460 nm) auto fluorescence outcome	inactive
Sample Source	SIGMA

 

Data for SID 103172948 in AID 1159620

First Approval	1982
MeSH ID	D063806
MeSH Heading	MYALGIA
EFO ID	HP:000332
EFO Term	MYALGIA
Max Phase for Indication	4
References	ATC;

 

Executive summary:

The PubChem BioAssay database was searched for chemogenomic, medicinal chemistry and functional genomics biological activities. 429 bioassays with 440 bioactivity outcomes were retrieved. DMSO was reported as inactive in 195 assays, inconclusive in 25 assays and active in 5 bioassays. Activity was unspecified for 215 assays. DMSO had no activity in cell viability assays, no agonist and/or antagonist activities on the peroxisome proliferator-activated receptor alpha (PPARa), delta (PPARd) and gamma (PPARg), antioxidant response element (ARE), androgen receptor (AR), estrogen receptor alpha (ER-alpha), thyroid receptor (TR) and glucocorticoid receptor (GR), p53, vitamin D receptor, retinoid X receptor alpha, farnesoid-X-receptor (FXR), hypoxia (HIF-1), NFkB, RXR, retinoid-related orphan receptor gamma (ROR-gamma) and aryl hydrocarbon receptor (AhR) signaling pathways. None of the reported positive assays was demonstrative of a toxicological activity.

Description of key information

Using a high-throughput robotic screening system (US EPA, 2017), DMSO was assessed for its potential to disrupt biological pathways (DNA binding, growth factor, nuclear receptor (non-steroidal and steroidal), cell cycle, cytochrome P450, hydrolase and cell morphology) that may result in toxicity. 316 assays were performed, DMSO induced a positive response in 2 assays (ATG_Ahr_CIS_up and NVS_ADME_hCYP19A1). In the NVS_ADME_hCYP19A1 assay, the biochemical assay was < 50% efficacy and both assays were flagged as borderline activity. Therefore, there is no evidence that DMSO could interfere with the expression of the screened genes.

The PubChem BioAssay database was searched for chemogenomic, medicinal chemistry and functional genomics biological activities (NCBI, 2017). 429 bioassays with 440 bioactivity outcomes were retrieved. DMSO was reported as inactive in 195 assays, inconclusive in 25 assays and active in 5 bioassays. Activity was unspecified for 215 assays. DMSO had no activity in cell viability assays, no agonist and/or antagonist activities on the peroxisome proliferator-activated receptor alpha (PPARa), delta (PPARd) and gamma (PPARg), antioxidant response element (ARE), androgen receptor (AR), estrogen receptor alpha (ER-alpha), thyroid receptor (TR) and glucocorticoid receptor (GR), p53, vitamin D receptor, retinoid X receptor alpha, farnesoid-X-receptor (FXR), hypoxia (HIF-1), NFkB, RXR, retinoid-related orphan receptor gamma (ROR-gamma) and aryl hydrocarbon receptor (AhR) signaling pathways. None of the reported positive assays was demonstrative of a toxicological activity.